ABSTRACT
Introduction
Over the last two decades, mitral transcatheter edge-to-edge repair (M-TEER) has become a safe and effective therapy for severe mitral regurgitation in patients deemed at high surgical risk.
Areas covered
This review aims to encompass the most relevant and updated evidence in the field of M-TEER from its inception, focusing on clinical and anatomical features for proper patient and device selection.
Expert opinion
Growing operator experience and device iterations have resulted in improved clinical outcomes and an expansion of the therapy to patients with complex anatomies and clinical scenarios. Future investigations are warranted to determine the best management options and the most suitable device for every patient with MR.
Article highlights
The experience and evidence with M-TEER have rapidly increased over the last decade.
Both MitraClip and PASCAL have proven to be safe and effective, with high procedural success and low rate of procedural complications
New-generation devices and advanced intraprocedural imaging techniques have expanded the anatomic eligibility for M-TEER
Patient and device selection remain the cornerstone of M-TEER therapy success
Declaration of interest
CHP Li and D Arzamendi are proctors for Abbott and Edwards. The other authors report no conflicts. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or material discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Author contributions
All authors were involved in the conception and design of the study; AMvR and LA executed data screening and analysis for the review; AMvR and LA produced the original draft writing; all authors reviewed and edited the manuscript for intellectual content; all authors have read and agreed to the published version of the manuscript